News
-
-
-
COMMUNIQUÉ DE PRESSE
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Salix Pharmaceuticals releases findings from first colonoscopy awareness survey, revealing insights on patient perspectives, barriers, and healthcare provider recommendations -
-
-
-
COMMUNIQUÉ DE PRESSE
Salix Announces 2024 Gastrointestinal Health Scholars Program
Bausch Health Companies Inc. has announced the 2024 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students with GI diseases. Applications open until May 6, 2024. Learn more at www.salix.com/scholarship -
COMMUNIQUÉ DE PRESSE
Bausch Health Announces Board Refreshment
Bausch Health Companies Inc. nominates two independent and diverse candidates, Christian A. Garcia and Frank D. Lee, for election to its Board of Directors. Russel C. Robertson and Thomas W. Ross, Sr. will retire from the Board, and the new nominees are expected to fill their roles. Bausch Health's 2024 Annual Meeting details will be included in the proxy statement -
COMMUNIQUÉ DE PRESSE
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
Bausch Health Companies Inc. (NYSE/TSX:BHC) will release Q4 and full-year 2023 financial results on Feb. 22, 2024, followed by a conference call and webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update -
COMMUNIQUÉ DE PRESSE
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Bausch Health and Ortho Dermatologics announced the U.S. launch of CABTREO Topical Gel, the first once-daily triple-combination topical treatment for acne vulgaris, approved by the FDA based on Phase 3 studies showing significant reductions in lesions